Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Meet us at CTAD 2026 in Boston, 16–⁠19 November: poster P446 on phone changes and speech measures. Find us in Boston ›

Speech biomarkers for DM1 and neuromuscular trials

Cephalgo gives DM1, late-onset Pompe disease and SMA trials more frequent readings of articulation, phonation and respiratory support from speech, in recordings you hold, site visits or home, stable across phone and software changes. Device changes ›

The problem

Bulbar and respiratory weakness is measured only at visits

In DM1, late-onset Pompe disease and SMA, the signs that speech carries are measured rarely.

Mostly at visits

Bulbar weakness is rated mostly at site visits, with little in between.

Small, varied cohorts

Rare-disease cohorts are small and span ages and severity, so every reading per participant counts.

Patient reports miss change

In DM1, reduced awareness of symptoms weakens patient-reported measures, so slow bulbar decline goes unreported.

By indication

Where speech adds a measure

Bulbar and respiratory weakness show in speech. Site-visit recordings and a few minutes at home add readings between visits, as an exploratory or secondary endpoint.

Myotonic dystrophy type 1

Dysarthria, hypernasal speech and oral myotonia, including the warm-up effect across repeated syllables. Read beside the communication subscale of the Myotonic Dystrophy Health Index (MDHI).

Late-onset Pompe disease

Phonation and respiratory support recorded upright and supine, read beside the site’s forced vital capacity (FVC) in the same positions.

Spinal muscular atrophy

Bulbar function in SMA, with tasks set per age and SMA type; for children, parental consent and assent as the protocol specifies. Read beside the bulbar items your protocol scores.

Joined to the visit score

Readings joined to the visit score, one line per participant. In dose‑finding studies, per‑arm readings go only to the independent unblinded statistician and data monitoring committee.

How speech readings work
A participant speaking with a study coordinator at a site visit, with an audio recorder on the table
Clinical validation

Validated in your study, against your reference

We compare our readings with the clinician-rated, patient-reported or measured reference your trial already runs.

Held-out participants

We evaluate on held‑out participants from your study, never used for calibration.

No black box

Each reading comes with the named speech features behind it and its analysis version, so any reading can be traced and rerun. Our pipeline ›

Small datasets

Our already-trained model is calibrated on screening and baseline data, blind to arm, locked before any post‑baseline reading. What goes into the analysis plan ›

Validation approach
Your referenceRead beside the reference your trial already runs
DM1
MDHI communication subscale
Late-onset Pompe
FVC upright and supine
SMA
Bulbar items your protocol scores
See our posters and white papers ›
Recordings you already hold

Re‑analysis of the DM1 and neuromuscular trials you already ran

Your past trials hold audio never read for speech. You get readings on the reference your trial used, from a completed or ongoing trial where consent covers further analysis. No new collection, no site burden, a fixed fee.

On your scale

You get a reading per recording, joined to the visit score, calibrated on screening and baseline ratings and locked blind to arm before post‑baseline recordings are read, so no post‑baseline data shapes the model.

For your next trial

You get variance components and, from a completed trial, an effect‑size estimate your statistician computes on the locked readings, so a small, varied cohort is sized on real data.

Joined to your reference

Readings joined to the MDHI communication subscale, FVC or bulbar items your trial recorded, per participant and visit.

Named features

You get the articulation, phonation and respiratory features behind every reading, so your team sees what moved.

Re‑analysis pilot
Re‑analysis pilotWhat you send, what comes back
You send
Recordings or an authorization to their holder (we draft it), visit scores and the consent scope
Readings
The reference your trial used, per recording
Planning
Effect size and variance for the next trial
Reference
MDHI, FVC or bulbar items, joined per visit
New collection
None
Fee and timeline
Fixed in writing before any data moves
In practice

How a session runs

Readings from audio you already hold, site-visit recordings, and home sessions via your eCOA or app vendor or the participant’s own phone.

Short spoken tasks

Sustained vowels, syllable repetition, reading or picture description, set per cohort and age, and read the same way in multilingual studies.

With the capture your study uses

Your eCOA or app vendor, or the participant’s own phone, with quality flags on every recording. Prospective study ›

The same reading after a phone update

When a participant’s phone updates or is replaced, you get readings recalibrated from the audio alone, blind to arm, so readings before and after the change sit on one scale. Device changes ›

Start a re-analysis pilot
Pre-screening

Check speech-related entry criteria before the screening visit

A short recording on the candidate’s own phone. Diagnosis, genetic confirmation, FVC and other measured criteria stay with the site.

Your entry criteria

Speech-related criteria in your protocol, such as a bulbar or speech score, read against an entry range fixed in writing before the first candidate.

Request a pre-screening scope
Questions

Cephalgo in neuromuscular trials

Which neuromuscular diseases does Cephalgo cover?

Cephalgo covers myotonic dystrophy type 1 (DM1), late-onset Pompe disease and spinal muscular atrophy (SMA), where bulbar and respiratory weakness show in speech.

Does Cephalgo work with small rare-disease cohorts?

Yes. Cephalgo’s already-trained model is calibrated on your study’s screening and baseline data, blind to arm, locked before any post‑baseline reading, and evaluated on held‑out participants.

Do phone and software changes affect speech biomarker readings in neuromuscular trials?

Phone and software changes shift speech measures. Cephalgo readings stay stable across them, recalibrated from the audio, so a change in articulation, phonation or respiratory support comes from the participant. Device changes ›

What are Cephalgo’s speech readings compared with?

Cephalgo compares its readings with your trial’s own reference: the MDHI communication subscale in DM1, upright and supine forced vital capacity in late-onset Pompe, and protocol bulbar items in SMA.

Discuss your neuromuscular program with our team

Bring the phase, population and endpoint, and any audio you already hold.

Request

We use your work email to send you the document and to follow up about it and related work. You can opt out at any time. Privacy policy

Thank you. We will send it to your work email.

Something went wrong. Please write to contact@cephalgo.com.